Fig. 2From: Tazemetostat decreases β-catenin and CD13 protein expression in HEPG-2 and Hepatitis B virus-transfected HEPG-2 with decreased cell viabilityPhase contrast images of different cell groups after 48 h of different treatments. a untreated HEPG2 cells; b HEPG2 with 0.05% DMSO; c HEPG2 with 1 μM Taz; d) HEPG2 transfected with hepatitis B virus (HBV/HEPG2); e HBV/HEPG2 with 0.05% DMSO; f HBV/HEPG2 with 1 μM Taz; Scale Bar: 100 µmBack to article page